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modelingBackground and purpose: To determine if there are differences between dose to pelvic bone marrow
(PBM) using intensity modulated radiotherapy (IMRT) under UK guidance versus conformal radiotherapy
(CRT) per ACT II protocol and if differences translate to rates of early haematological adverse events grade
3 or greater (HT3+).
Methods and materials: Two groups of 20+ patients, treated under IMRT and CRT regimes respectively,
were identified. All patients underwent weekly blood cell count: haemoglobin (HgB), white cell count
(WCC), absolute neutrophil count (ANC) and platelets (plats).
Percent volume of PBM and sub structures receiving 5–25 Gy were tested for statistical significance.
Regression models were used to test for correlation to blood counts. NTCP modeling was also performed.
Results: PMB dose metrics showed a significant increase in the IMRT group. Regression analysis showed
iliac and lumbosacral PBM dose metrics to associate with reduced nadir ANC andWCC. NTCP at HT3+ was
0.13 using IMRT relative to 0.07 using CRT (p < 0.05).
Conclusion: Whilst this is a relatively small retrospective study and lacks information on the distribution
of active PBM, IMRT treatment has been shown to significantly increase PMB irradiation. PBM dose met-
rics have been shown to be predictive of WCC and ANC suppression. NTCP modeling predicts much high
risk of HT3+. Paradoxically, actual rates of HT3+ were comparable suggesting that differences in the dis-
tributions of dose metrics maybe a significant factor and/or that there are insufficiency in the NTCP
modeling.
 2015 The Authors. Published by Elsevier Ireland Ltd. Radiotherapy and Oncology 117 (2015) 246–251
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).Radical chemoradiation is the standard treatment in
loco-regional anal cancer, achieving a 3 year disease free survival
of 73% with organ preservation [1–3]. Recently, there has been
an increasing move from conformal to intensity-modulated radio-
therapy (IMRT). IMRT can deliver varying dose levels to multiple
targets while decreasing low to intermediate dose (V30 Gy,
V40 Gy etc.) to organs at risk, reducing adverse events (early
gastrointestinal and dermatological, grade 3+) [4]. However, the
impact of IMRT in delivering a ‘low dose bath’ to normal tissue
needs to be considered in this tumour type, particularly in the con-
text of concurrent chemotherapy. This impact is most pronounced
in highly chemo-radiation sensitive tissue such as bone marrow
(BM). Increased irradiation of BM has been shown to increase
likelihood of early haematologic adverse events (HT) [5,6].
Approximately one third of proliferating bone marrow is locatedin the pelvic bones [7]; therefore differences in delivery system
in anal irradiation may result in significant changes in rates of early
adverse events. Irradiation of BM in IMRT can be reduced by apply-
ing appropriate dose objectives in the optimisation, i.e. through
sparing [8], but this is not routinely done during the planning
process.
UK ACT II trial delivering a 2 phase conformal radiotherapy
(CRT) technique reported early haematologic adverse events grade
3 or 4 (HT3+) in the mitomycin arm as 26% [2]. The US Radiation
Therapy Oncology Group (RTOG) 98–11 trial reported maximum
grade 3 of 35% and max grade 4 in 26% of patients recruited in
the mitomycin arm [3]. The RTOG 0529 trial looking at IMRT for
anal cancer reported 58% HT3+ (4). Other US IMRT studies which
have reported HT3+ at 24 and 53% [9,10].
This study aims to determine differences in pelvic bone marrow
(PBM) dose associated with IMRT per UK guidelines (IMRT group),
relative to CRT per ACT II (CRT group), and implications on acute
haematological toxicity.
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Patient selection
Twenty-five and twenty-one anal cancer patients treated with
CRT and IMRT chemoradiotherapy respectively were identified in
this retrospective study. Patients were treated in two sequential
blocks in 2009 and 2014 respectively. Patients had a diagnosis of
anal carcinoma with squamous carcinoma (one adenocarcinoma,
IMRT group), disease localised to the pelvis, were radiotherapy
naïve and considered fit enough with adequate baseline bloods
by the treating clinician for radiotherapy alone or chemoradiother-
apy. Patient gender, age, tumour staging and nodal status were
collected.Treatment
Radiotherapy
Twenty-five patients were treated as per ACT II protocol [2],
using a two phase CRT technique. Phase one was a two field
(anterior-posterior parallel opposing) technique to 30.6 Gy in 17
fractions which covered primary tumour, anal canal and elective
nodes, field borders were placed superiorly 2 cm above the bottom
of the sacroiliac joints, inferiorly 3 cm below anal margin or 3 cm
below the most inferior extent of tumour, laterally to femoral
heads. Phase two was a standard three field CRT technique to
19.8 Gy in 11 fractions covering gross tumour. The gross tumour
was delineated by the treating oncologist with a margin of 3 cm
added to create the PTV. No constraint was placed on pelvic bone
dose including dose to femoral heads.
21 patients were treated using 7–9 field IMRT in 28 fractions
using simultaneous integrated boost. Delineation was as per UK
guidance [11]. In summary, gross anal tumour plus a 2.5 cm mar-
gin received either 53.2 Gy (if T3 and T4) or 50.4 Gy (if <T3); the
involved nodes plus a 2 cm margin received 50.4 Gy and the pro-
phylactic nodes received 39.2 (12 patients) or 40 Gy (9 patients)
due to the protocol being updated during the audit period. A con-
straint was placed on femoral head dose (dose to 50% less than
30 Gy, dose to 35% less than 40 Gy and dose to 5% less than
44 Gy) but dose to other pelvic bone structures was unconstrained.
Chemotherapy
Patients fit enough for concurrent chemotherapy were planned
to receive either Mitomycin 12 mg/m2 Day 1 monotherapy if
5-fluorouracil was contraindicated, Mitomycin 12 mg/m2 and
5FU 1000 mg/m 2 Days 1–5 and 29–33. 1 patient had Mitomycin
12 mg/m2 Day 1 with Capecitabine 825 mg/m2 twice daily on all
days of radiotherapy. The second course of 5-fluorouracil was
reduced by 25 or 50% following any episodes of any Grade 3
non-haematological related toxicity such as diarrhoea or Grade
3–4 haematological toxicity. 5-Fluorouracil was withheld at Grade
4 non-haematological toxicity and Capecitabine was withheld with
thrombocytopenia Grade 2 or neutropenia G3 or any Grade 3 non-
haematological toxicity related to Capecitabine; until it resolved to
G1 then restarted at the same dose or at a reduced dose.Bone marrow delineation
Pelvic bone marrow (PBM) was delineated using the external
surface of bone and sub divided into three components; iliac BM,
extending from the iliac crest to the superior edge of femoral head,
lower pelvis BM, extending from the superior edge of femoral
heads and including all pelvic bone as well as proximal femoral
bone down to the level of and including the inferior ischial
tuberosities, and lumbosacral BM, extending from the level of the
superior border of L5 to the superior edge of femoral heads. Subdivision of BM was based on previously published work by Mell
et al. [5,6]. The method of delineating BM using the external sur-
face of bone is consistent with the Radiation Therapy Oncology
Group (RTOG) 0418 clinical trial as well as the aforementioned pre-
vious published work [5,6].Dose metrics
The percent volume of pelvic, iliac, lower pelvis and lum-
bosacral BM receiving 5, 10, 15, 20 and 25 Gy (V5–25) was
extracted. IMRT and CRT group dose metrics were compared using
a two tailed Mann–Whitney U test.Blood parameter analysis
Haemoglobin (HgB), white cell count (WCC) including absolute
neutrophil count (ANC) and platelets (Plats) were determined from
blood samples collected at baseline and weekly during radiother-
apy. In addition to absolute counts, blood count ratios were calcu-
lated by dividing counts at each week by baseline count. Toxicity
was graded using Common Terminology Criteria for Adverse
Events, version 4.0. Maximum toxicity grading during radiotherapy
was noted for each patient. Analysis endpoints were blood count
nadirs, blood count ratio nadirs and whether a patient had experi-
enced acute HT3+. IMRT and CRT group blood count nadirs were
tested using a two tailed unpaired Student t-test assuming unequal
variance.
Dose metrics were compared with analysis endpoints using uni-
variate and multivariate linear and logistic regression models to
determine if statistically significant correlation to decreasing nadir
blood counts, both absolute and count ratio, and increasing HT3+
probability could be established. Covariants of female gender,
age, T3/4 and node positive status were also compared using
regression models. Additionally, weekly blood counts and count
ratios were compared between groups using a two tailed unpaired
Student t-test assuming unequal variance.
Significance testing using the Holm–Bonferroni method of cor-
rection for multiple testing was applied. False discovery rate was
controlled at 5%. In regression analysis false discovery rate was
controlled at 5% for analysis of whole PBM and each PBM sub struc-
tures dose metrics against each individual blood count for IMRT
and CRT groups separately.NTCP modeling
Lyman–Kutcher–Burman (LKB) NTCP [12] modeling on PBM
was performed using parameter value estimates and 95% CI taken
from previously published work by Bazan et al. [13] which esti-
mated HT3+ parameter values based on anal cancer patients
receiving mitomycin plus fluorouracil (mitomycin 10 mg/m2 on
day 1 and 29 with fluorouracil 1000 mg/m2 on days 1–3 and days
29–32). Constraining n to one (i.e. treating bone marrow as an
entirely parallel organ), m was reported as 0.09 (95% CI, 0.4–0.3)
and TD50 as 30 Gy (95% CI, 28–32 Gy). NTCP was calculated using
Eqs. (1–4) [14] where v i is the volume within dose bin Di at 0.1 Gy
intervals and e is the number of fractions. The alpha beta ratio ab
 
of PBM was taken as 10 Gy n.b. In the case of CRT plan Deff was the
sum of Deff calculated for each phase.
NTCP ¼ ð2piÞ0:5
Z x
1
exp  t
2
2
 
dt ð1Þ
x ¼ Deff  TD50
m TD50 ð2Þ
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Mean age was 66 yrs (44–88), 27/46 were female, 23/46 were
T3–4 and 19/46 were node positive, 13/46 were both T3–4 and
node positive. A breakdown of patient characteristics including
chemo regime in each group is shown in Supplementary Table 1.
With the exception of lower pelvis BM V25 all BM metrics
showed statistically significant increase in the IMRT versus CRT
group (p 6 0.02). Table 1 shows all dose metrics in both groups.
Four cases of leukopenia/neutropenia and 1 leukopenia were
reported in the CRT group (20% HT3+) relative to one leukopenia,
one leukopenia/neutropenia and one thrombocytopenia in the
IMRT group (14% HT3+). Mean baseline bloods, absolute and ratio
nadir counts are shown in Table 2. Blood count nadir did not show
statistically significant difference between IMRT and CRT groups.Table 1
Pelvic bone marrow and sub component dose metrics in conformal and intensity-
modulated radiotherapy.
CRT IMRT
Mean SD Mean SD
Whole pelvis BM
Volume (cm3) 1399.6 253.1 1335.6 245.8
V5 (%) 60.4 12.9 89.8 4.3
V10 (%) 57.3 12.5 82.6 4.7
V15 (%) 53.9 12.0 78.7 4.8
V20 (%) 48.7 11.7 73.8 5.2
V25 (%) 46.7 11.7 64.4 7.3
Iliac BM
Volume (cm3) 481.7 82.2 453.3 73.5
V5 (%) 40.1 19.5 83.0 7.4
V10 (%) 35.7 17.9 68.7 7.4
V15 (%) 33.2 16.6 61.5 6.8
V20 (%) 30.8 14.7 56.2 5.6
V25 (%) 28.4 14.7 47.5 6.6
Lumbosacral BM
Volume (cm3) 317.6 65.1 312.7 62.2
V5 (%) 24.0 24.0 81.1 9.9
V10 (%) 19.8 23.0 71.4 11.5
V15 (%) 17.6 22.6 67.0 11.7
V20 (%) 16.3 22.1 63.1 11.9
V25 (%) 15.1 21.7 59.8 12.1
Lower pelvis BM
Volume (cm3) 599.6 119.5 569.6 128.0
V5 (%) 95.9 7.5 100.0 0.0
V10 (%) 94.4 9.1 100.0 0.2
V15 (%) 89.5 9.4 99.0 1.6
V20 (%) 80.0 8.9 93.9 6.6
V25 (%) 77.9 9.0 80.7 11.2
Abbreviations: CRT = conformal radiotherapy; IMRT = intensity modulated radio-
therapy; SD = standard deviation; BM = bone marrow.
Table 2
Blood count baseline and nadir, both absolute and as a ratio of baseline.
CRT group
Baseline bloods Nadir (absolute)
HgB (g/dl) 12.9 (8.8–16.0) 11.4 (9.2–14.0)
WCC (109/l) 8 (3.4–17.9) 3.1 (1.2–6.6)
ANC (109/l) 5.1 (1.2–14.9) 1.9 (0.4–5.0)
Platelets (109/l) 274.5 (144.0–611.0) 125.4 (44.0–208.0)
Abbreviations: CRT = conformal radiotherapy; IMRT = intensity modulated radiotherapy;Univariate linear regression of the CRT group dose metrics
against bloods showed iliac and lumbosacral BM V5–25 to have
statistically significant association to a reduced nadir HgB
(p < 0.02). Lower pelvis BM V5–25 showed statistically significant
association to a reduced nadir Plats (p < 0.01). Lower pelvis V5–
15 showed statistically significant association to a reduced nadir
WCC and ANC (p 6 0.03) but not after multiple testing was
accounted for. Iliac V5–25 showed association to nadir WCC only
(p < 0.05). All other dose metrics failed to demonstrate statistical
significance. Univariate linear regression of the IMRT group dose
metrics against bloods also showed iliac BM V15 and lumbosacral
BM V10–25 dose metrics to have statistically significant associa-
tion to a reduced nadir HgB (p < 0.05) but both failed significant
testing after multiple testing was accounted for. Iliac V25 was sug-
gestive of an association to reduced nadir WCC but it was not sig-
nificant (p = 0.09). Lower pelvis V5–15 were not shown to associate
with nadir WCC or ANC, however average V15 was 99%. All other
dose metrics showed statistically insignificant association to
reduced nadir bloods. Table 3 shows significant regression analysis
result.
Weekly blood counts were not statistically significantly differ-
ent in the IMRT and CRT group at any week. In both groups nadir
counts occurred at week 2–3 followed by a recovery at week 4.
Univariate linear regression analysis of nadir absolute blood
counts with covariates showed female gender to be a statistically
significant association to reduced nadir in all counts: Beta 0.89
and 0.7, SE 0.4 and 0.32 and p 0.03 and 0.03.
Multiple linear regression analysis did not show dose metrics to
be significantly associated with nadir blood counts. Univariate and
multi variant logistic regression analysis also did not show dose
metrics to be significantly associated with HT3+ using either IMRT
or CRT.IMRT group
Nadir (ratio) Nadir (absolute) Nadir (ratio)
0.89 (0.76–1.00) 10.9 (8.7–14.5) 0.87 (0.63–0.99)
0.42 (0.22–0.83) 3.2 (0.8–5.0) 0.38 (0.15–0.62)
0.42 (0.16–0.97) 2.2 (0.6–3.8) 0.42 (0.15–0.83)
0.52 (0.26–0.88) 139.9 (49.0–372.0) 0.46 (0.14–0.77)
HgB = haemoglobin; WCC = white cell count; ANC = absolute neutrophil count.
Table 3
Univariate linear regression results of pelvis bone marrow dose metrics against
absolute nadir blood counts.
Conformal IMRT
Nadir WCC (109/l) Nadir WCC (109/l)
Beta SE p Beta SE p
Iliac BM V25 0.044 0.02 0.038 0.061 0.033 0.086
V20 0.046 0.02 0.029 0.047 0.041 0.27
V15 0.039 0.017 0.036 0.02 0.035 0.574
V10 0.035 0.016 0.042 0.02 0.035 0.574
V5 0.032 0.015 0.046 0.036 0.031 0.259
Lower pelvis BM V25 0.05 0.033 0.139 0.02 0.021 0.355
V20 0.054 0.033 0.117 0.03 0.035 0.412
V15 0.069 0.03 0.03 NA NA NA
V10 0.081 0.03 0.013 NA NA NA
V5 0.089 0.037 0.027 NA NA NA
Nadir ANC (109/l) Nadir ANC (109/l)
Lower pelvis BM V15 0.054 0.024 0.032 0.068 0.121 0.577
V10 0.064 0.024 0.013 NA NA NA
V5 0.071 0.029 0.024 NA NA NA
Abbreviations: CRT = conformal radiotherapy; IMRT = Intensity Modulated Radio-
therapy; BM = bone marrow.
Table 4
Univariate linear regression results of pelvis bone marrow dose metrics against nadir
blood counts expressed as a ratio of baseline.
CRT IMRT
Nadir WCC ratio Nadir WCC ratio
Beta SE p Beta SE p
Whole pelvis BM_V25 0.009 0.004 0.064 0.003 0.004 0.347
Whole pelvis BM_V20 0.009 0.004 0.055 0.008 0.005 0.095
Whole pelvis BM_V15 0.010 0.005 0.052 0.014 0.004 0.005
Whole pelvis BM_V10 0.011 0.005 0.029 0.015 0.004 0.003
Whole pelvis BM_V5 0.010 0.004 0.033 0.015 0.005 0.008
Iliac BM_V25 0.008 0.003 0.008 0.005 0.004 0.211
Iliac BM_V20 0.008 0.003 0.008 0.012 0.004 0.010
Iliac BM_V15 0.007 0.003 0.008 0.011 0.003 0.004
Iliac BM_V10 0.007 0.002 0.007 0.010 0.003 0.004
Iliac BM_V5 0.007 0.002 0.009 0.010 0.003 0.004
Lumbosacral BM_V25 0.009 0.005 0.070 0.006 0.002 0.004
Lumbosacral BM_V20 0.008 0.004 0.069 0.006 0.002 0.004
Lumbosacral BM_V15 0.008 0.004 0.067 0.006 0.002 0.002
Lumbosacral BM_V10 0.007 0.004 0.060 0.006 0.002 0.004
Lumbosacral BM_V5 0.006 0.003 0.061 0.006 0.002 0.024
Nadir ANC ratio Nadir ANC ratio
Whole pelvis BM_V25 0.008 0.005 0.125 0.004 0.006 0.503
Whole pelvis BM_V20 0.008 0.005 0.115 0.011 0.008 0.221
Whole pelvis BM_V15 0.010 0.005 0.062 0.020 0.008 0.027
Whole pelvis BM_V10 0.010 0.005 0.043 0.021 0.008 0.018
Whole pelvis BM_V5 0.009 0.005 0.063 0.020 0.009 0.045
Iliac BM_V25 0.007 0.003 0.057 0.003 0.007 0.636
Iliac BM_V20 0.007 0.003 0.059 0.013 0.008 0.100
Iliac BM_V15 0.007 0.003 0.058 0.013 0.006 0.048
Iliac BM_V10 0.007 0.003 0.056 0.012 0.006 0.054
Iliac BM_V5 0.006 0.003 0.052 0.011 0.006 0.096
Lumbosacral BM_V25 0.004 0.004 0.332 0.009 0.003 0.014
Lumbosacral BM_V20 0.003 0.003 0.316 0.009 0.003 0.011
Lumbosacral BM_V15 0.003 0.003 0.300 0.009 0.003 0.007
Lumbosacral BM_V10 0.004 0.003 0.259 0.009 0.003 0.008
Lumbosacral BM_V5 0.003 0.003 0.225 0.009 0.004 0.035
Abbreviations: CRT = conformal radiotherapy; IMRT = intensity modulated radio-
therapy; WCC = white cell count; ANC = absolute neutrophil count; BM = bone
marrow.
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ference in the IMRT population relative to the CRT. Univariate lin-
ear regression of the CRT group dose metrics against blood count
ratios is shown in Table 4. Iliac V5–25 was shown to be signifi-
cantly associated to reduced WCC (p < 0.01) and suggestive of an
association to reduce ANC nadir (p < 0.1). Lumbosacral BM V5–25
suggested an association to reduced WCC nadir only (p > 0.05 but
<0.06). Iliac V5–25 dose metrics were associated with reduced
plats ratio (p < 0.02). Univariate linear regression of the IMRT
group dose metrics against blood count ratios showed iliac V5–
20 to be significantly associated to reduced WCC nadir (p < 0.01)
with V10 and 15 suggestive of an association (p = 0.053 and
0.048) to nadir ANC. All lumbosacral dose metrics were signifi-
cantly associated to both reduced WCC and ANC nadir (p < 0.05).
Analysis of blood count ratios showed nadir blood count again
occurred at week 2–3, a greater relative recovery was seen in the
CRT group but was not shown to be significant. Weekly blood
count ratios are shown in Fig. 1.
Female gender was not associated with reduced ratios suggest-
ing that although baseline counts are reduced the relative suppres-
sion is consistent with that seen in men. T3/4 was associated to
reduced nadir WCC and ANC in the IMRT group only: Beta 0.12
and 0.2, SE 0.05 and 0.09, p 0.03 and 0.04 for WCC and ANC
respectively.
Multiple linear regression analysis did not show dose metrics to
be significantly associated with nadir blood count ratios.
Increase in NTCP using parameter values given by Bazan et al.
[13] in the IMRT group was statistically significant (p < 0.05). MeanNTCP at HT3+ was 0.13 (0.00–0.82) using IMRT relative to 0.07
(0.00–0.93) using CRT. Mean NTCP based on 95% CI parameter esti-
mates were 3–39% in the IMRT group and 4–18% in the CRT group.
Comparing against recorded toxicity in this study sample, NTCP
modeling well predicted toxicity in the IMRT but predicted toxicity
in the CRT group lay marginally outside 95% CI NTCP modeling.Discussion
This study looked at PBM doses and blood counts in anal cancer
patients receiving concurrent chemoradiation using either IMRT
under UK guidelines or CRT per ACT II trial protocol. This study
has shown PBM dose to be increased using IMRT. This increase is
attributable to the low dose bath associated with IMRT delivery
combined with differences in dose regime and PTV delineation.
Regression analysis showed the majority of dose metrics to be
associated with lower nadir blood counts, with strongest associa-
tions seen at 10–15 Gy, and NTCP modeling based on Bazan et al.
[13] parameters was predictive of a doubling of risk associated
with IMRT. HgB was little suppressed with minimum nadir count
78% of baseline. However, this study does lack data on transfusion;
these patients may have received to support HgB. Plats were sup-
pressed but generally speaking not to an extent where HT3+ rates
would be a clinical concern. The suppression of WCC and ANC and
rates of leukopenia and neutropenia is clinically significant.
Weekly treatment response pattern was found to be consistent
between groups; in both groups nadir absolute count occurred at
week 2–3, this is consistent with responses seen in rectal patients
in the US where nadir counts were seen at week 2 [15]. However,
neither absolute nor blood count ratios where statistically signifi-
cant and PBM dose metrics could not be associated to HT3+ rates.
Despite greater mean PBM dose metrics using IMRT and signif-
icant association of PBM dose metrics with lower nadir blood
counts, actual rates of HT3+ using IMRT were comparable with
rates using CRT. This, somewhat paradoxical finding, may be
explained by looking at the distribution of PBM dose metrics in
the two groups. IMRT PBM doses show a much narrower distribu-
tion. A likely hypothesis is that whilst mean PBM dose is higher,
doses do not exceed a critical level and therefore IMRT treatment
does not significantly impact HT3+ rates under UK practice. This
finding is potentially significant given mean PBM dose metrics in
the IMRT group were comparable to those reported in the US by
Mell et al. [5] (iliac BM V5–20 was 83–56% compared with 85–
55%, lumbosacral BM V5–20 was 81–63% compared with 82–66%
and lower pelvis BM V5–20 100–94% compared with 99–92%) yet
rates were considerably lower at 14% relative to >50%. This is
despite 16/21 (76%) of patients exceeding suggested HT3+ dose tol-
erances for PBM and BM (lumbosacral). One possible explanation is
that PBM doses in the Mell study did not share the tight distribu-
tion reported in the study, this is supported when looking at the
standard deviation of dose metrics in the Mell study which are
approximately double those reported here. This, combined with
other differences in practice, may explain the much higher rates
seen in the US for comparable mean PBM doses.
The distribution of PBM dose metrics may also explain the
incorrect prediction by the NTCP model of double the risk on
HT3+, but insufficiencies in the NTCP model in this setting maybe
a more dominate factor.
On regression analysis, lumbosacral BM doses were either asso-
ciated with or suggestive of reduced nadir WCC and ANC ratios in
both groups. This finding is consistent with findings reported by
Mell et al. [5] and Bazan et al. [13] where lumbosacral BM doses
were shown to be associated with absolute WCC and ANC count.
Strongest associations were seen in iliac BM to reduced nadir
WCC, decreasing absolute WCC nadir were reported by Mell et al.
Fig. 1. Weekly blood cell counts expressed as a ratio of baseline (mean and standard deviation) during radiotherapy showing intensity modulated (IMRT) versus conformal
radiotherapy (CRT) sample populations. HgB: hemoglobin, WCC: white cell count, ANC: absolute neutrophil count.
250 Pelvic radiotherapy haematologic toxicitybut none were found to be statistically significant (p > 0.1 in each
case). Reducing PBM at the 10–15 Gy level may reduce suppression
and subsequent HT3+ rates. Significant sparing of lumbosacral at
the 10–15 Gy dose level is challenging due to overlapping struc-
tures and the relative position of gross tumour volume. Sparing
of iliac BM is more achievable. From univariate regression analysis
each percent iliac BM V10–15 can be associated with a relative
reduction from baseline of 1% in WCC and 1–2% ANC.
As female gender has been shown to be a significant covariant
factor, this study supports any dose tolerances used to guide spar-
ing being gender specific as in Mell et al. [5] n.b. ratio analysis did
not show female gender to be predictive of count ratio nadir, as
was also found by Yang et al. [15] in rectal patients, showing treat-
ment response is independent of gender.
This retrospective study is limited in its relatively small sample
size and the compounding factor of concurrent chemotherapy in
determining the precise radiosensitivity of PBM. Subsequently,
the results of this work should be interpreted in the context of
the concurrent chemotherapy regime and with an awareness of
the sample size. Another limitation is that we do not have any infor-
mation on the function distribution of active bonemarrow; FLT-PET
has been used to spatially define activemorrow [16] and could have
indicated the highly proliferative zones of marrow irradiated. How-
ever, analysis of both CRT and IMRT patients in this study is a
strength in determining the response of PBM to irradiation.
In conclusion, IMRT treatment is associated with a significant
increase in dose to PBM relative to CRT treatment. PBM dose met-
rics are predictive of WCC and ANC suppression in IMRT treatment
with each additional percent of iliac/lumbosacral PBM deliveredbeing associated with 1–2% decrease in WCC and ANC. NTCP mod-
eling suggests IMRT results in an approximately doubled risk of
HT3+ compared to CRT. Despite this increased PBM dose did not
translate into higher rates of HT3+ in this study; the influence of
distribution spread of PBM dose metrics on observed HT3+ rates
is worthy of further investigation.
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